Given the swathe of recent success stories in alternative proteins, not least the November 2022 approval by FDA of Upside Foods' chicken, the truth is this is only the only the start. Consumers will in part be driven by price, especially with a cost-of-living crisis. To achieve commercial viability in cultured meat, major challenges exist in scalability. To scale up, costs must come down – drastically – in culture media, equipment, and clean rooms. We also need to overcome bottlenecks related to the industrial-scale production of cultured meat products. Companies will therefore need to develop scalable, streamlined manufacturing facilities and ensure robust supply chains, requiring large capital investment in manufacturing capability to achieve production levels that will allow cultured meat to penetrate the consumer market in an impactful way. If, as industry experts predict, cultured meat will achieve price parity with traditionally-farmed meat by 2030, we need huge advances the cost of cell media and growth factors, the availability of suitable cell lines, affordable and suitable extracellular matrics, improved bioreactor design and efficiency and enhancements in scaffolding materials and design. In this panel, we will hear from experts that are making all of these dreams a reality.